Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

Muhler P, AkuamoaBoateng D, Rosenbrock J, et al. Cost–utility analysis of MR imaging-guided transurethral ultrasound ablation for the treatment of low- to intermediate-risk localised prostate cancer. BMJ Open 2025;15:e088495. doi:10.1136/bmjopen-2024-088495

This article has been corrected since it was published online.

Page 1

'BACKGROUND

[...] Among all prostate cancer patients, those with low or favourable intermediate risk of prostate cancer who have a low risk of tumour

& page 2

'[...] To evaluate the clinical and economic long-term consequences of applying MR-TULSA in low or favourable intermediate-risk prostate cancer in Germany'

We found inconsistencies in punctuation: Please correct them into 'low- and favourable intermediate-risk (of) prostate cancer.

Page 5:

'Table 2 Cost calculation [...] Salvage ADT withleuprorelinn for 2 years'

The typing mistake mentioned above, needs to be corrected in 'with leuprorelin for 2 years'

Page 5:

'Table 2 Cost calculation [...] RARP, radical prostatectomy'

Please correct to 'RARP, robot-assisted radical prostatectomy'.

Page 6:

'DISCUSSION This is the first cost–utility analysis of MR-TULSA for the treatment of low- and favourable intermediate-risk localised prostate cancer. Our results show that over a lifetime horizon, RARP is the cheapest treatment alternative, whereas AS and MR-TULSA are cost-effective alternatives with an ICER of €116 600 per QALY and €12 193...'

Instead of the correct value €11600 per QALY, it is written €116600 per QALY. Page 7:

'Strength and limitations [...] To respond to the degree of uncertainty of long-term outcomes (eg, mortality) from different treatment strat egies for low-risk prostate cancer, a series of structural sensitivity analyses were conducted, exploring shorter time horizons for the model (10, 15 and 20 years).

Instead of 10, 15 and 20 years, we conducted structural sensitivity analyses in the model for 5, 10 and 20 years as mentioned in 'METHODS' (page 4).

Please replace the highlighted text with the required corrections.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

BMJ Open 2025;15. doi:10.1136/bmjopen-2024-088495corr1



